Juan Carlos Martínez-Pastor

Dr. Juan Carlos Martínez-Pastor


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMarta Sabater-Martos
Marta Sabater-Martos
LBLaia Boadas-Girones
Laia Boadas-Girones
LMLaura Morata
Laura Morata
ASAlex Soriano
Alex Soriano
JMJuan Carlos Martínez-Pastor
Juan Carlos Martínez-Pastor
Background: The treatment of periprosthetic joint infection (PJI) involves various strategies, with debridement, antibiotic, and implant retention (DAIR) being a preferred method for acute infections due to its lower morbidity. However, DAIR success rates vary widely from 30% to 80%. This study investigates the predictive value of synovial glucose and the serum-to-synovial glucose ratio for DAIR outcomes in acute postoperative PJI following total knee arthroplasty (TKA). Methods: This is a retrospective study of 32 DAIR cases, diagnosed with acute postoperative PJI after TKA. Synovial joint aspirations were performed on all patients. We collected all serological and synovial glucose levels. The serum-to-synovial glucose ratio was calculated. Results: Patients with synovial glucose levels below 44 mg/dL and a serum-to-synovial glucose ratio above 50% were identified as high risk for DAIR failure. High-risk patients exhibited a 31.3% failure rate, with half occurring within the first three months post-DAIR. No failures were observed in the low-risk group. Multivariate analysis did not find other significant predictors such as CRP levels, gender, or microbial cultures. Conclusions: Low synovial glucose levels and high serum-to-synovial glucose ratios are predictive of unsuccessful outcomes following DAIR procedures. Patients exhibiting lower synovial concentrations experienced early treatment failure.

5 August 2025 in International Orthopaedics
Verified
Journal Article
Open access
PDF file
JPJuan Carlos Perdomo-Lizárraga
Juan Carlos Perdomo-Lizárraga
ACAndrés Combalia
Andrés Combalia
JFJenaro A Fernández-Valencia
Jenaro A Fernández-Valencia
JMJuan Carlos Martínez-Pastor
Juan Carlos Martínez-Pastor
AAAlfonso Alías
Alfonso Alías
EMErnesto Muñoz-Mahamud
Ernesto Muñoz-Mahamud
Introduction: Debridement, antibiotics, and implant retention (DAIR) is a commonly employed strategy for managing acute postoperative prosthetic joint infections (PJI) while preserving the prosthesis. However, the clinical value of an unplanned second DAIR - performed due to inadequate infection control - remains controversial and is often considered a potential treatment failure. This study aimed to compare the two year clinical outcomes of patients undergoing a single DAIR versus those requiring an unplanned second DAIR for acute postoperative PJI of the hip or knee. Methods: We retrospectively reviewed electronic medical records of patients treated with DAIR for acute postoperative PJI between January 1999 and December 2020. Patients were categorized into two groups: those managed with a single DAIR (DAIR-1 group) and those requiring an unplanned second DAIR within 12 weeks (DAIR-2 group). Treatment failure was defined as any of the following: further debridement beyond 12 weeks, revision surgery with prosthesis removal, initiation of long-term suppressive antibiotic therapy, or PJI-related mortality. Patients lost to follow-up before two years were excluded. Results: A total of 318 patients were included, with 292 in the DAIR-1 group and 26 in the DAIR-2 group. Mean follow-up was 89.4 months. At two years, revision surgery was required in 19.2% (56/292) of DAIR-1 patients and 42.3% (11/26) of DAIR-2 patients (p = 0.005). Overall failure-free survival at two years was observed in 75.3% (220/292) of DAIR-1 patients compared to 46.2% (12/26) of those in the DAIR-2 group (p = 0.001). Conclusion: Unplanned second DAIR procedures are associated with significantly lower success rates at two years. Nonetheless, given that nearly half of these patients remained free of failure, a second DAIR may still be a reasonable therapeutic option in selected cases, provided that the increased risk of a poorer prognosis is taken into account.